National Peroxide Q3 FY26: Marginal Recovery Masks Deeper Structural Concerns

The December 2025 quarter represents a modest operational improvement for the Wadia Group-controlled chemical manufacturer, with net sales rising 1.17% quarter-on-quarter to ₹69.09 crores and 11.15% year-on-year. However, this recovery follows a disastrous FY25 where the company posted a net loss of ₹2.00 crores on revenues of ₹286.00 crores, representing a dramatic reversal from the ₹16.00 crore profit in FY24. The company's operating profit margin of 10.12% in Q3 FY26, whilst the highest in seven quarters, remains substantially below the 13.81% achieved in Q2 FY25, highlighting the volatility and fragility of its business model.

Trading at ₹427.50 as of February 06, 2026, National Peroxide's shares have shown recent resilience with a 6.79% gain over the past week, but remain 44.48% below their 52-week high of ₹770.00. The stock's dramatic underperformance against both the Sensex and its commodity chemicals peer group, combined with a "STRONG SELL" rating and an overall score of just 17 out of 100, underscores the market's deep scepticism about the company's ability to sustain any meaningful turnaround.

Financial Performance: Fragile Recovery on Weak Foundations

National Peroxide's Q3 FY26 results reveal a company struggling to establish consistent operational momentum. Net sales of ₹69.09 crores represent only a marginal 1.17% sequential improvement from Q2 FY26's ₹68.29 crores, whilst the year-on-year comparison of 11.15% growth is flattered by the exceptionally weak base of December 2024 when revenues stood at ₹62.16 crores. More concerning is the broader trend: nine-month revenues for FY26 stand at ₹204.04 crores, still tracking well below the company's historical run-rate and reflecting the structural demand challenges facing the business.

The operating profit margin improvement to 10.12% in Q3 FY26, whilst encouraging, must be viewed with considerable caution. This metric has exhibited wild swings, ranging from a negative 3.20% in March 2025 to 13.81% in June 2024, suggesting the company lacks pricing power and operational stability. Employee costs declined to ₹6.41 crores in Q3 FY26 from ₹7.08 crores in Q1 FY26, but this reduction appears tactical rather than strategic. The company's profit before tax of ₹1.78 crores in Q3 FY26, whilst positive, compares unfavourably to the ₹6.82 crores achieved in Q2 FY25, highlighting how far profitability has deteriorated.

Perhaps most troubling is the quality of earnings. The company recorded a negative tax rate of -2.81% in Q3 FY26, suggesting tax credits or adjustments that artificially boosted reported net profit. Other income of ₹0.90 crores, whilst lower than previous quarters, continues to represent a meaningful proportion of pre-tax profits, raising questions about the sustainability of core operations. The PAT margin of 2.65% in Q3 FY26, though improved from Q2 FY26's 0.57%, remains drastically below the 6.87% achieved in Q2 FY25, underscoring the erosion in profitability.

Operational Challenges: Deteriorating Returns Signal Structural Issues

The company's return metrics paint a deeply concerning picture of capital efficiency. The average Return on Equity (ROE) stands at a meagre 1.90%, with the latest quarterly ROE at -1.92%, indicating that the company is destroying shareholder value rather than creating it. For context, a healthy manufacturing company should deliver ROE in the mid-teens at minimum; National Peroxide's single-digit returns suggest fundamental issues with either pricing power, cost structure, or asset productivity. The average Return on Capital Employed (ROCE) of 3.99% is equally anaemic, barely exceeding risk-free rates and signalling that the company's invested capital is generating inadequate returns.

The balance sheet reveals a company that, whilst not overleveraged, is struggling to deploy its assets productively. Fixed assets of ₹304.62 crores as of March 2025 represent the bulk of the ₹349.26 crore shareholder funds, yet these assets are generating minimal returns. Long-term debt has declined from ₹13.89 crores in March 2023 to ₹3.52 crores in March 2025, which is positive, but this deleveraging has come at the cost of profitability rather than through operational excellence. The company maintains a net cash position with a debt-to-equity ratio of -0.14, yet this financial strength has not translated into operational performance.

Working capital management appears adequate, with current assets of ₹120.81 crores exceeding current liabilities of ₹36.62 crores, providing a comfortable cushion. However, the sales-to-capital-employed ratio of 0.87 indicates that the company is generating less than one rupee of sales for every rupee of capital employed, a clear sign of asset underutilisation. The five-year sales CAGR of -12.60% and the catastrophic five-year EBIT CAGR of -135.58% underscore the severity of the operational deterioration.

Industry Context: Underperforming in a Challenging Sector

The commodity chemicals sector has faced headwinds from volatile raw material prices, subdued demand from downstream industries, and intense competition. National Peroxide's 40.21% stock price decline over the past year significantly underperforms the commodity chemicals sector average return of 4.96%, representing an alarming 45.17 percentage point underperformance. This suggests company-specific issues beyond broader sectoral challenges.

Whilst peers have navigated the difficult environment with varying degrees of success, National Peroxide's struggles appear more acute. The company's inability to maintain pricing power, as evidenced by wildly fluctuating margins, suggests it operates in commoditised product segments with limited differentiation. The five-year revenue decline of 12.60% annually contrasts sharply with the growth trajectories of better-positioned competitors, indicating market share losses or exposure to declining end-markets.

The company's position as a micro-cap with minimal institutional interest (just 0.01% institutional holdings) further limits its ability to access capital or attract investor attention. Without a clear strategic repositioning or operational turnaround plan, National Peroxide risks remaining a structurally challenged player in an already difficult sector.

Peer Comparison: Lagging on All Key Metrics

A comparison with commodity chemicals peers reveals National Peroxide's competitive disadvantages across multiple dimensions. The company's ROE of 1.90% trails significantly behind peers such as Lords Chloro (19.73%), Andhra Petrochemicals (16.69%), and Alufluoride (17.91%). Even Kanoria Chemicals, another struggling player, matches National Peroxide's weak 1.60% ROE, highlighting how far the company has fallen.

The price-to-book ratio of 0.67x, whilst appearing attractive on a superficial level, actually reflects the market's assessment that the company's assets are worth less than their book value due to poor returns. Peers with stronger operational performance command premium valuations: Alufluoride trades at 3.08x book value, whilst Lords Chloro commands 1.94x. National Peroxide's discount is not an opportunity but a warning signal about asset quality and earning power.

The inability to command a P/E multiple due to loss-making status places National Peroxide in the same category as distressed peers. Whilst the company maintains a net cash position, this financial conservatism has not translated into operational excellence or shareholder returns. The peer comparison underscores that National Peroxide's challenges are company-specific rather than sector-wide, making a turnaround more difficult to achieve.

Valuation Analysis: Discount Reflects Fundamental Weakness

National Peroxide's valuation metrics tell a story of a company trapped in a value trap. The price-to-book ratio of 0.67x suggests the market values the company's assets at a 33% discount to their stated book value of ₹607.73 per share. This discount is not unjustified given the company's inability to generate adequate returns on these assets. With an ROE of just 1.90%, the market is essentially saying that the book value overstates the true economic worth of the business.

The EV/EBITDA multiple of 18.41x appears elevated, but this is misleading given the depressed EBITDA base. With an enterprise value of ₹196.90 crores and trailing twelve-month EBITDA of approximately ₹10.70 crores, the company is valued at nearly 19 times a metric that itself reflects poor operational performance. The negative EV/EBIT ratio of -18.05x reflects the company's operating losses, making traditional valuation frameworks largely irrelevant.

The stock's valuation grade has deteriorated from "Attractive" to "Risky" as of May 2025, reflecting the market's recognition of the company's structural challenges. Trading at ₹427.50, down 44.48% from its 52-week high of ₹770.00, the stock has destroyed substantial shareholder wealth. The dividend yield is not applicable given the company's current profitability challenges, though it historically paid ₹12.50 per share in dividends when performance was stronger.

Shareholding: Promoter Stability Amidst Institutional Exodus

The shareholding pattern reveals a company with stable promoter commitment but virtually no institutional interest. Promoter holding has remained constant at 70.76% across the last five quarters, indicating that the Wadia Group-controlled entities backing National Peroxide have not wavered in their commitment. Key promoter entities include Nowrosjee Wadia And Sons Limited (30.78%), Baymanco Investments Limited (20.38%), and Macrofil Investments Limited (12.99%), all part of the Wadia Group ecosystem.

However, the complete absence of Foreign Institutional Investor (FII) and Mutual Fund holdings is a glaring red flag. Institutional holdings stand at a negligible 0.01%, limited to minor DII participation, indicating that professional investors see no investment merit in the stock. This lack of institutional sponsorship severely limits the stock's liquidity and potential for re-rating, as institutional buying is typically necessary to drive sustained price appreciation in small-cap stocks.

The complete stagnation in shareholding pattern over five quarters suggests that neither institutions nor retail investors see value in accumulating the stock. The non-institutional holding of 29.22% likely comprises retail investors trapped in legacy positions. With zero pledging of promoter shares, at least the company avoids the governance concerns associated with pledged holdings, but this alone cannot compensate for the fundamental operational weaknesses.

Stock Performance: Severe Underperformance Across All Timeframes

National Peroxide's stock performance has been catastrophic across virtually all meaningful timeframes. The one-year return of -40.21% compares devastatingly to the Sensex's 6.36% gain, representing a negative alpha of -46.57 percentage points. This underperformance is not merely a function of sector headwinds, as evidenced by the commodity chemicals sector's positive 4.96% return over the same period. The stock's 45.17 percentage point underperformance versus its sector peers highlights company-specific issues.

The six-month return of -34.42% against the Sensex's 3.08% gain demonstrates that the underperformance has accelerated in recent months, coinciding with the company's deteriorating financial results. The three-month return of -26.22% shows continued weakness, with only marginal recent improvement reflected in the one-week gain of 6.79% and one-day gain of 4.43%. These short-term bounces appear to be technical in nature rather than reflecting any fundamental improvement.

The stock's beta of 1.50 indicates it is 50% more volatile than the broader market, amplifying both gains and losses. However, with consistently negative returns, this high beta has worked entirely against shareholders. The risk-adjusted return of -1.02 and volatility of 39.50% place the stock in the "HIGH RISK LOW RETURN" category, the worst possible combination for investors. The stock trades below all key moving averages, with the current price of ₹427.50 sitting 27% below the 200-day moving average of ₹585.18, confirming the entrenched bearish trend.

Investment Thesis: Multiple Red Flags Outweigh Single Quarter Recovery

National Peroxide's investment thesis is fundamentally broken across all four key parameters that drive long-term stock performance. The proprietary Mojo Score of just 17 out of 100 and a "STRONG SELL" rating reflect the confluence of negative factors that make this stock uninvestable at current levels, despite the marginal Q3 FY26 recovery.

Valuation (RISKY): The company's valuation metrics offer no margin of safety. Trading at 0.67x book value appears cheap, but this discount reflects the market's accurate assessment that the company cannot generate adequate returns on its asset base. With an ROE of 1.90%, the economic value of the business is substantially below its book value.

Quality (BELOW AVERAGE): The quality assessment is damning. A five-year sales CAGR of -12.60% and five-year EBIT CAGR of -135.58% indicate a business in structural decline. The average ROCE of 3.99% and ROE of 1.90% demonstrate chronic capital inefficiency. Whilst the company maintains zero debt and no promoter pledging, these positives cannot compensate for the fundamental operational weaknesses.

Financial Trend (POSITIVE): The short-term financial trend turned positive in Q3 FY26, marking the highest operating profit margin in seven quarters. However, this single quarter's improvement must be viewed against the backdrop of a disastrous FY25 and ongoing structural challenges. The trend is fragile and could easily reverse.

Technical Trend (BEARISH): The technical picture is unambiguously negative. The stock has been in a bearish trend since November 2025, trading below all major moving averages. MACD, KST, and Dow Theory all signal bearish conditions. The recent one-week bounce appears to be a technical dead-cat bounce rather than a trend reversal.

Key Strengths & Risk Factors

Outlook: What Lies Ahead